




INTRALIFE
PRIVATE LIMITED

Annually,
15 Million People
WORLDWIDE...



**...SUFFER A
STROKE**

Of these, 5 million die & another 5 Million
are left permanently disabled,

**World Health
Organization**

SIXABEN 5/2.5

Apixaban 5mg / 2.5 mg Tablets

SIXABEN 5 2.5

Apixaban 5mg / 2.5 mg Tablets

An orally available Factor Xa inhibitor, inhibits free & clot-bound FXa and prothrombinase activity. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development *

A highly selective direct factor Xa inhibitor, blocking the propagation phase of the coagulation cascade **

More effective for stroke prevention & systemic embolism¹


Appropriate alternative to Vitamin K Antagonist like warfarin for preventing stroke in patients with atrial fibrillation²

The risk of major bleeding is significantly lower for apixaban compared with warfarin, dabigatran & rivaroxaban³

Compared to warfarin and rivaroxaban, apixaban has a much lower risk of intracranial haemorrhage⁴

APPROVED FOR 6 INDICATIONS

DEEP VEIN THROMBOSIS | PULMONARY EMBOLISM
PROPHYLAXIS OF DVT IN PATIENTS UNDERGONE
KNEE & HIP REPLACEMENT SURGERY



Quick
onset of
action

Safe along
with PPI
& H2RA

Administered
with or without
Food

THE RECOMMENDED DOSE of **SIXABEN 5 mg** orally **bid**.

If patients fulfilling at least two (2) of the following criteria, age > 80 years, body weight < 60 kg, or serum creatinine > 133 micromole/L (1.5 mg/dL), a reduced dose of **SIXABEN 2.5 mg twice daily** is recommended.



1. PLoS One. 2018; Jan 26;13(1):e0191722. 2. European heart journal. 2014 Jul 21;35(28):1864-72.

3. Stroke. 2018 Jan;49(1):98-106. 4. Jama. 2021 Dec 21;326(23):2395-404.

* Cardiology research and practice. 2019 Jul 7;2019. ** European heart journal. 2014 Jul 21;35(28):1864-72

REDUCES STROKE RISK - BETTER THAN WARFARIN